Current barriers to treatment for wet age-related macular degeneration (wAMD): findings from the wAMD patient and caregiver survey

Monica Varano,1 Nicole Eter,2 Steve Winyard,3 Kim U Wittrup-Jensen,4 Rafael Navarro,5 Julie Heraghty6On behalf of the wAMD Patient and Caregiver Survey Committee members1Department of Ophthalmology, Fondazione GB Bietti-IRCCS, Rome, Italy; 2Department of Ophthalmology, University of Münster...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Varano M, Eter N, Winyard S, Wittrup-Jensen KU, Navarro R, Heraghty J
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2015
Materias:	Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/dbb8d06aa46e4226b36e810d3a8ced42
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:dbb8d06aa46e4226b36e810d3a8ced42
record_format	dspace
spelling	oai:doaj.org-article:dbb8d06aa46e4226b36e810d3a8ced422021-12-02T00:22:14ZCurrent barriers to treatment for wet age-related macular degeneration (wAMD): findings from the wAMD patient and caregiver survey1177-5483https://doaj.org/article/dbb8d06aa46e4226b36e810d3a8ced422015-12-01T00:00:00Zhttps://www.dovepress.com/current-barriers-to-treatment-for-wet-age-related-macular-degeneration-peer-reviewed-article-OPTHhttps://doaj.org/toc/1177-5483Monica Varano,1 Nicole Eter,2 Steve Winyard,3 Kim U Wittrup-Jensen,4 Rafael Navarro,5 Julie Heraghty6On behalf of the wAMD Patient and Caregiver Survey Committee members1Department of Ophthalmology, Fondazione GB Bietti-IRCCS, Rome, Italy; 2Department of Ophthalmology, University of Münster, Münster, Germany; 3Department of Policy and Campaigns, Royal National Institute of Blind People, London, UK; 4Bayer Pharma AG, Berlin, Germany; 5Instituto de Microcirugía Ocular, Barcelona, Spain; 6Macular Disease Foundation Australia, Sydney, NSW, AustraliaPurpose: A cross-sectional survey to evaluate the current management of wet age-related macular degeneration (wAMD) and to identify barriers to treatment from a patient and caregiver perspective.Methods: An ophthalmologist-devised questionnaire was given to a global cohort of patients who were receiving (or had previously received) antivascular endothelial growth factor injections and to caregivers (paid and unpaid) to evaluate the impact of wAMD on their lives.Results: Responders included 910 patients and 890 caregivers; wAMD was diagnosed in both eyes in 45% of patients, and 64% had been receiving injections for >1 year. Many caregivers were a child/grandchild (47%) or partner (23%) of the patient; only 7% were professional caregivers. Most (73%) patients visited a health care professional within 1 month of experiencing vision changes and 54% began treatment immediately. Most patients and caregivers reported a number of obstacles in managing wAMD, including the treatment itself (35% and 39%, respectively). Sixteen percent of patients also missed a clinic visit.Conclusion: Most patients seek medical assistance promptly for a change in vision; however, about a quarter of them do not. This highlights a lack of awareness surrounding eye health and the impact of a delayed diagnosis. Most patients and caregivers identified a number of obstacles in managing wAMD.Keywords: antivascular endothelial growth factor agents, patient-reported outcomes, wAMD patient and caregiver survey, wet age-related macular degenerationVarano MEter NWinyard SWittrup-Jensen KUNavarro RHeraghty JDove Medical PressarticleOphthalmologyRE1-994ENClinical Ophthalmology, Vol 2015, Iss default, Pp 2243-2250 (2015)
institution	DOAJ
collection	DOAJ
language	EN
topic	Ophthalmology RE1-994
spellingShingle	Ophthalmology RE1-994 Varano M Eter N Winyard S Wittrup-Jensen KU Navarro R Heraghty J Current barriers to treatment for wet age-related macular degeneration (wAMD): findings from the wAMD patient and caregiver survey
description	Monica Varano,1 Nicole Eter,2 Steve Winyard,3 Kim U Wittrup-Jensen,4 Rafael Navarro,5 Julie Heraghty6On behalf of the wAMD Patient and Caregiver Survey Committee members1Department of Ophthalmology, Fondazione GB Bietti-IRCCS, Rome, Italy; 2Department of Ophthalmology, University of Münster, Münster, Germany; 3Department of Policy and Campaigns, Royal National Institute of Blind People, London, UK; 4Bayer Pharma AG, Berlin, Germany; 5Instituto de Microcirugía Ocular, Barcelona, Spain; 6Macular Disease Foundation Australia, Sydney, NSW, AustraliaPurpose: A cross-sectional survey to evaluate the current management of wet age-related macular degeneration (wAMD) and to identify barriers to treatment from a patient and caregiver perspective.Methods: An ophthalmologist-devised questionnaire was given to a global cohort of patients who were receiving (or had previously received) antivascular endothelial growth factor injections and to caregivers (paid and unpaid) to evaluate the impact of wAMD on their lives.Results: Responders included 910 patients and 890 caregivers; wAMD was diagnosed in both eyes in 45% of patients, and 64% had been receiving injections for >1 year. Many caregivers were a child/grandchild (47%) or partner (23%) of the patient; only 7% were professional caregivers. Most (73%) patients visited a health care professional within 1 month of experiencing vision changes and 54% began treatment immediately. Most patients and caregivers reported a number of obstacles in managing wAMD, including the treatment itself (35% and 39%, respectively). Sixteen percent of patients also missed a clinic visit.Conclusion: Most patients seek medical assistance promptly for a change in vision; however, about a quarter of them do not. This highlights a lack of awareness surrounding eye health and the impact of a delayed diagnosis. Most patients and caregivers identified a number of obstacles in managing wAMD.Keywords: antivascular endothelial growth factor agents, patient-reported outcomes, wAMD patient and caregiver survey, wet age-related macular degeneration
format	article
author	Varano M Eter N Winyard S Wittrup-Jensen KU Navarro R Heraghty J
author_facet	Varano M Eter N Winyard S Wittrup-Jensen KU Navarro R Heraghty J
author_sort	Varano M
title	Current barriers to treatment for wet age-related macular degeneration (wAMD): findings from the wAMD patient and caregiver survey
title_short	Current barriers to treatment for wet age-related macular degeneration (wAMD): findings from the wAMD patient and caregiver survey
title_full	Current barriers to treatment for wet age-related macular degeneration (wAMD): findings from the wAMD patient and caregiver survey
title_fullStr	Current barriers to treatment for wet age-related macular degeneration (wAMD): findings from the wAMD patient and caregiver survey
title_full_unstemmed	Current barriers to treatment for wet age-related macular degeneration (wAMD): findings from the wAMD patient and caregiver survey
title_sort	current barriers to treatment for wet age-related macular degeneration (wamd): findings from the wamd patient and caregiver survey
publisher	Dove Medical Press
publishDate	2015
url	https://doaj.org/article/dbb8d06aa46e4226b36e810d3a8ced42
work_keys_str_mv	AT varanom currentbarrierstotreatmentforwetagerelatedmaculardegenerationwamdfindingsfromthewamdpatientandcaregiversurvey AT etern currentbarrierstotreatmentforwetagerelatedmaculardegenerationwamdfindingsfromthewamdpatientandcaregiversurvey AT winyards currentbarrierstotreatmentforwetagerelatedmaculardegenerationwamdfindingsfromthewamdpatientandcaregiversurvey AT wittrupjensenku currentbarrierstotreatmentforwetagerelatedmaculardegenerationwamdfindingsfromthewamdpatientandcaregiversurvey AT navarror currentbarrierstotreatmentforwetagerelatedmaculardegenerationwamdfindingsfromthewamdpatientandcaregiversurvey AT heraghtyj currentbarrierstotreatmentforwetagerelatedmaculardegenerationwamdfindingsfromthewamdpatientandcaregiversurvey
_version_	1718403834615693312

Current barriers to treatment for wet age-related macular degeneration (wAMD): findings from the wAMD patient and caregiver survey

Ejemplares similares